FibroGen ’s antibody fails PhIII in Duchenne muscular dystrophy
FibroGen’s top antibody candidate has failed a Phase III study in Duchenne muscular dystrophy, marking a disappointing start to a string of readouts slated for the next few months. Dubbed pamrevlumab, the drug is listed as a lead candidate for FibroGen alongside…#dubbedpamrevlumab #unlock
Source: Reuters: Health - Category: Consumer Health News Source Type: news